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Background: Chinese herbal medicine (CHM) has been commonly used for treating osteoarthritis in Asia for
centuries. This study aimed to conduct a large-scale pharmaco-epidemiologic study and evaluate the frequency
and patterns of CHM used in treating osteoarthritis in Taiwan.
Methods: A complete database (total 22,520,776 beneficiaries) of traditional Chinese medicine (TCM) outpatient
claims offered by the National Health Insurance program in Taiwan for the year 2002 was employed for this
research. Patients with osteoarthritis were identified according to the diagnostic code of the International
Classification of Disease among claimed visiting files. Corresponding prescription files were analyzed, and an
association rule was applied to evaluate the co-prescription of CHM for treating osteoarthritis.
Results: There were 20,059 subjects who visited TCM clinics for osteoarthritis and received a total of 32,050 CHM
prescriptions. Subjects between 40 and 49 years of age comprised the largest number of those treated (19.2%),
followed by 50-59 years (18.8%) and 60-69 years group (18.2%). In addition, female subjects used CHMs for
osteoarthritis more frequently than male subjects (female: male = 1.89: l). There was an average of 5.2 items
prescribed in the form of either an individual Chinese herb or formula in a single CHM prescription for
osteoarthritis. Du-zhong (Eucommia bark) was the most commonly prescribed Chinese single herb, while
Du-huo-ji-sheng-tang was the most commonly prescribed Chinese herbal formula for osteoarthritis. According
to the association rule, the most commonly prescribed formula was Du-huo-ji-sheng-tang plus Shen-tong-zhu-
yu-tang, and the most commonly prescribed triple-drug combination was Du-huo-ji-sheng-tang, Gu-sui-pu
(Drynaria fortune (Kunze) J. Sm.), and Xu-Duan (Himalaya teasel). Nevertheless, further clinical trials are needed to
evaluate the efficacy and safety of these CHMs for treating osteoarthritis.
Conclusions: This study conducted a large scale pharmaco-epidemiology survey of Chinese herbal medicine
use in OA patients by analyzing the NHIRD in Taiwan in year 2002.
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Osteoarthritis (OA) is a degenerative joint disease which
relates to aging, and affects the joint of hands, hips,
knees, spine, and feet [1,2]. OA is the most common
form of joint disease in human sparing no race or geo-
graphic area [3-5]. It affected 33.6% older people in the
United States [6], and the cost of artificial knee and hip
replacements for severe OA were $42.3 billion in 2009
[7]. Patients with OA suffered from swelling and pain of
joints, limitation of joint motion range, limitation in
walking and stair climbing, and lower quality of life [8].
The managements for OA includes weight reduction,
rehabilitation, and pharmacologic therapies [9]. The
most common western medicine used in treating OA is
non-steroidal anti-inflammatory drugs, but some people
had adverse drug reactions like gastrointestinal ulcer,
bleeding and renal insufficiency [10]. OA is one of the
most common musculoskeletal diseases in Taiwan. The
incidence rate of OA was 37% among people aged over
50 years old in Taiwan [11].
The etiology of OA is still not fully clear, but the age,
genetic, biomechanical, inflammatory, and metabolic
changes of joints are the main factors [12,13]. And
obesity may alter daily biomechanical exposures and
make a damage effects on inflammation in OA joints
[14]. Several literatures have elucidated that pro-
inflammatory cytokines and anti-inflammatory cyto-
kines like IL-1, IFN-γ, IL-6, IL-7, IL-10 and TNF-α
were elevated in the OA joints [15-17]. In addition, the
osteoporosis is highly associated with the prevalence of
OA in menopausal women [18-20]. And the subchon-
dral bone loss was a feature of osteoporosis and the
early stage of OA [21].
Since there are many adverse side effects of conven-
tional western medication in treating OA [22], more and
more OA patients use complementary and alternative
medicine (CAM) to improve the symptoms and signs of
the disease joints [23]. Chinese herbal medicine [24,25],
acupuncture [26], dry cupping [27], herbal patch [28] or
other CAM therapies [29] were the common CAM widely
accepted by OA patients.
National Health Insurance (NHI) is a universal health
insurance program executed since 1995 in Taiwan which
covers both western medicine and traditional Chinese
Medicine (TCM) [30]. Near 98% of all inhabitants in
Taiwan were covered in the NHI program at the end of
2002 [31]. However, there were no nationwide population
based surveys of CHM used in treating OA so far.
Methods
In this study, we use the complete NHI database of 2002
which covered the entire population of 22,520,776 bene-
ficiaries in Taiwan to survey the utilization and patterns
of CHM for TCM outpatients’ clinics.Data sources
National Health Insurance Research Dataset (NHIRD) is
an electronic claim data that contains nationwide medical
records of National Health Insurance (NHI) since 1995 in
Taiwan. We collected the information including genders,
ages, birthdays, dates of encounters, and disease diagnosis
of patients from the NHIRD in the year 2002 from out-
patient visiting file (CM_CD2002.DAT) and the corre-
sponding prescription files (CM_OO2002.DAT) were also
identified. And this study was assessed to the TCM out-
patient visits in the NHRID was approved by the Taipei
Veterans General Hospital. International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) was used to define the study population with the
diagnosis of OA (ICD code: 715). Patients and institutional
privacies were protected by scrambling cryptogram. Data
of Chinese herbal formulae and Chinese single herbs were
provided in prescription files, which could reveal the pre-
scription and the utilization patterns.
The details of NHIRD data have been described in previ-
ous prescription patterns and the utilization analysis of
CHM in different diseases like insomnia [32], constipation
[33], chronic hepatitis [34], inflammatory bowel disease
[35], liver cancer [36] and allergic rhinitis [37].
Study design
Although “pattern identification as the basis for determin-
ing treatment“ is the key concept for treating patients in
TCM which is different from that of Western medicine
doctors, the TCM doctors in Taiwan still have to use ICD-
9-CM codes to make a diagnosis for outpatient visits.
Since OA has several types, the ICD-9-CM codes 715.0
(Osteoarthrosis, generalized), 715.1 (Osteoarthrosis, local-
ized, primary), 715.2 (Osteoarthrosis, localized, secondary),
715.3 (Osteoarthrosis, localized, not specified whether
primary or secondary), 715.9 (Osteoarthrosis, unspeci-
fied whether generalized or localized), 716.1 (Traumatic
arthropathy) and 716.9 (Arthropathy, unspecified) were
all extracted as target study subjects among the outpa-
tients visits in this study.
Data analysis
We used the Structure Query Language (SQL server 2008,
Microsoft Corp., Redmond, WA USA) for data linkage ana-
lysis and processing. Frequency and patterns of Chinese
formulae or Chinese single herbs use were taken into regu-
lar statistics by the Statistical Package for Social Science
version 19.0 (SPSS Inc., Chicago, IL USA). Association rule
was applied when we used International Business Machines
DB2 8.1 (IBM, Armonk, NY USA) for co-prescribing pre-
scriptions. As the support factor and confidence factor were
the main determining factors, in this study, we set 0.4% as
the minimum support factor and 30% as the minimum
confidence level.
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There were totally 6,221,426 TCM outpatients (27.6%)
treated by CHM among the 22,520,776 beneficiaries under
the NHI in 2002. Among these TCM outpatients, 37,163
(0.6%) patients were diagnosed with OA. In this study, we
extracted 20,059 patients (54.0%) who visited the TCM
outpatient clinics with the single diagnosis of OA. There
were totally 32,609 CHM prescriptions for these 20,059
patients. Female patients preferred using CHM for OA
more than male patients (female: male = 1.89: 1). Patients’
age between 40 and 49 years had the highest prevalence
rate (19.2%), followed by age 50-59 years (18.2%), 60-
69 years (18.2%) and 70-79 years (15.9%). Table 1 demon-
strates the age-sex-specific frequency of CHM used in OA
patients.
The top 10 Chinese single herbs for osteoarthritis in
CHM were showed in Table 2. Du-zhong (Eucommia
ulmoides, 15.6%) was the most common used Chinese
single herb, followed by Xu-duan (Dipacus asper, 13.8%),
Niu-xi (Achyranthes bidentata, 11.7%), Mu-gua (Chaeno-
meles lagenaria, 10.1%), Dan-sen (Salvia miltiorrhiza,
9.7%), Ji-xue-teng (Spatholobus suberectus Dunn, 8.5%),
Yan-hu-suo (Corydalis yanhusuo, 7.8%), Wei-ling-zian
(Clematis chinensis Osbeck, 7.3%), Ru-xiang (Boswellia
carterii Birdw, 5.4%), Mo-yao (Commiphora myrrha
Engl., 5.2%) and Gu-sui-pu (Drynaria fortune (Kunze) J.
Sm., 4.9%).
Among the total 32,069 CHM prescriptions for treat-
ing OA, the top 10 Chinese herbal formulae were
showed in Table 3. The most common used Chinese
herbal formula was Du-huo-ji-sheng-tang (26.6%), the
followed by Shu-jiang-hou-xie-tang (24.3%), Dang-gui-
nian-tung-tang (11.1%), Liu-wei-di-huang-wan (8.7%),
Ji-sheng-shen-qi-wan (6.6%), Chi-po-ti-huang-wan (6.5%),
Kou-qi-di-huang-wan (5.9%), Xue-fu-chu-yu-tang (5.3%),
Gui-zhi-shuo-yao-zhi-mu-tang (4.8%), Shou-yao-gan-tsao-
tang (4.4%) and Jia-wei-xiao-yao-san (3.9%).Table 1 Age-sex-specific frequency for the use of Chinese her
national health insurance in Taiwan during 2002
Age (years) Subjects with osteo







> = 80 821 4.1%
Total 20,059 100.0%
*male: female = 1:1.89.Analyzing the prescription pattern of CHM for OA,
we found that a patient was given the average of 5.2
CHM in a single prescription. Six items of CHM (20.4%,
Figure 1) was the most common CHM prescription with
the combination of Chinese herbal formulae or Chinese
single herbs, followed by 5 CHMs (19.6%) and 4 CHM
combination (15.9%). We used the association rule to
evaluate the co-prescription pattern of Chinese formula
and Chinese single herb (Table 4 and Table 5). The most
common combination of two CHM was “Shu-jiang-
hou-xie-tang plus Du-huo-ji-sheng-tang”, followed by
“Jia-wei-xiao-yao-san plus Du-huo-ji-sheng-tang”, and
“Jia-wei-xiao-yao-san plus Shu-jing-huo-zue-tang”. The
most common combination of triple CHM was “Du-
huo-ji-sheng-tang, Gu-sui-pu plus Xu-duan”, followed
by were “Du-huo-ji-sheng-tang, Yan-hu-suo plus Nui-
xi”, “Du-huo-ji-sheng-tang, Shu-jing-huo-zue-tang plus
Yan-hu-suo” and “Du-zhong, Xu-duan plus Gu-sui-pu”.
Discussion
This study is the first nationwide population based survey
of the CHM use for OA patients in Taiwan. Females used
CHM for OA higher than males (1.89:1), and the female
aged 50-69 years had the highest prevalence of CHM use
for OA. Menopause, higher percentage of obesity and
osteoporosis in female may be the factors accounting for
this phenomenon [38-40].
OA patients were treated with the thought of “pattern
identification as the basis for determining treatment” by
TCM physicians, and the prescriptions were different
among TCM doctors according to their individual personal
experience and their knowledge of Traditional Chinese
herbs. There were few large-scale pharmaco-epidemiologic
surveys of OA patients with CHM use. By analyzing the na-
tionwide TCM outpatient clinic medical record from the
NHIRD, we can evaluate the utilization and prescription
patterns of CHM in treating OA.bal medicines in patients with osteoarthritis under the
arthritis using Chinese herbal medicines
Male (%) Female (%)
916 (43.8%) 1,177 (56.2%)
940 (35.1%) 1,741 (64.9%)
1,274 (33.1%) 2,579 (66.9%)
1,115 (29.6%) 2,651 (70.4%)
1,035 (29.6%) 2,619 (70.4%)
1,280 (40.1%) 1,911 (59.9%)
386 (47.0%) 435 (53.0%)
6,946* (34.6%) 13,113* (65.4%)
Table 2 The top 10 individual Chinese herbs prescribed for osteoarthritis in Taiwan during 2002 (total prescription
numbers = 32,050)
Chinese single herb (Chinese name) Generic name Number of prescriptions Percentage
Du-zhong Eucommia ulmoides 5,005 15.6%
Xu-duan Dipsacus asper 4,419 13.8%
Niu-xi Achyranthes bidentata 3,763 11.7%
Mu-gua Chaenomeles lagenaria 3,240 10.1%
Dan-sen Salvia miltiorrhiza 3,115 9.7%
Ji-xue-teng Spatholobus suberectus Dunn 2,721 8.5%
Yan-hu-suo Corydalis yanhusuo 2,494 7.8%
Wei-ling-xian Clematis chinensis Osbeck 2,354 7.3%
Ru-xiang Boswellia carterii Birdw. 1,715 5.4%
Mo-yao Commiphoramyrrha Engl. 1,674 5.2%
Gu-sui-pu Drynaria fortune (Kunze) J. Sm. 1,569 4.9%
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most common used Chinese herbal formula for OA. Lai
et al. [41] conducted a prospective clinical study to ob-
serve 68 patients with OA knees who were treated with
“Du-huo-ji-sheng-tang” for 4 weeks in 2005. They eval-
uated the knee condition with the Western Ontario and
McMaster Universities Arthritis Index (WOMAC) [42],
which is widely used in evaluating knee and hip OA
with three dimensions including pain, disability and
joint stiffness. They concluded that the WOMAC index
scores were decreased after treatment, and the patients’
pain and stiffness in knees were released. In addition,
their physical function were improved after treatment.
Chen et al. [43] used “Du-huo-ji-sheng-tang” , osami-
nethacine and placebo in an anterior cruciate ligament





Du-huo-ji-sheng-tang Du-huo, Sang-ji-sheng, Ren-sen, Fu-ling, Ga
Chuan-qiong, Di-huang, Gui-zhi, Du-zhong
Shu-jiang-hou-xie-tang Dang-gue, Gan-cao, Shao-yao, Di-huang ,
Wei-ling-xian, Chuan-qiong, Fang-ji, Qiang
Dang-gui-nian-tung-tang Qiang-huo, Yin-chen-hao, Huang-qin, Gan-
Dang-guei, Cang-zhu, Ge-gen, Ren-sen, Ku
Liu-wei-di-huang-wan Di-huang, San-zhu-yu, Shan-yao, Mu-dan-
Ji-sheng-shen-qi-wan Di-huang, Shan-yao, San-zhu-yu, Ze-xie, Fu
Chi-po-ti-huang-wan Zhi-mu, Huang-bo, Di-huang, San-zhu-yu,
Kou-qi-di-huang-wan Gou-ci, Ju-hua, Di-huang, San-zhu-yu, Sha
Xue-fu-chu-yu-tang Dang-guei, Di-huang, Tao-ren, Hong-hua,
Chuan-qiong, Niu-xi
Gui-zhi-shuo-yao-zhi-mu-tang Gui-zhi, Shao-yao, Bai-zhu, Zhi-mu, Ma-hu
Shou-yao-gan-tsao-tang Shao-yao, Gan-cao
Jia-wei-xiao-yao-san Dang-guei, Fu-ling, Zhi-zi, Bo-he, Shao-yao,and proposed that histological degeneration of carti-
large in “Du-huo-ji-sheng-tang” group was lower than
the osaminethacine group and the control group. In this
animal model, Du-huo-ji-sheng-tang” could inhibit
chondrocytes apoptosis and could also regulate the ex-
pression of vascular endothelial growth factor (VEGF)
mRNA, hypoxia-inducible factor (HIF) -1α mRNA.
“Shu-jiang-hou-xie-tang” was the second common
Chinese herbal formula for OA in this study, and it was
also the third common CHM formula for menopause in a
previous literature [40]. It had been proved to have effects
in treating musculoskeletal disease and connective tissue
[44], and had effects of pain relief with the mechanism of
increasing blood circulation in the adjuvant arthritis rats
model [45]. The third common Chinese herbal formula




, Niu-xi, Xi-xin, Fang-feng, Qin-jiao
8,538 (26.6%)
Bai-zhu, Niu-xi, Chen-pi, Tao-ren,
-huo, Bai-zhi, Long-dan-cao, Fu-ling, Sheng-jiang
7,804 (24.3%)
cao, Zhi-mu, Zhu-ling, Ze-xie, Fang-feng,
-sen, Sheng-ma, Bai-zhu
3,560 (11.1%)
pi, Ze-xie, Fu-ling 2,779 (8.7%)
-ling, Mu-dan-pi, Rou-gui, Fu-zi, Niu-xi, Che-qian-zi 2,126 (6.6%)
Shan-yao, Ze-xie, Mu-dan-pi, Fu-ling 2,081 (6.5%)
n-yao, Ze-xie, Mu-dan-pi, Fu-ling 1,904 (5.9%)
Zhi-shi, Shao-yao, Chai-hu, Gan-cao, Jie-geng, 1,702 (5.3%)
ang, Gan-cao, Fang-feng, Sheng-jiang, Fu-zi 1,532 (4.8%)
1,411 (4.4%)
Chai-hu, Gan-cao, Bai-zhu, Mu-dan-pi, Sheng-jiang 1,249 (3.9%)













Figure 1 Relationship between the number of prescriptions in Taiwan in 2002 and the number of Chinese single herbs or combined
ingredients of Chinese herbal formulae for subjects with osteoarthritis.
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perimental OA rats [46].
According to our results, “Du-zhong” was the most com-
mon used Chinese single herb in treating OA, and it was
also one of the compositions in Du-huo-ji-sheng-tang. In
the experiments of ovariectomy-induced rats, it could re-
duce postmenopausal osteoporosis, body weight, body
mass index and fat tissue [47,48]. And “Du-zhong” was also
the most common used Chinese single herb in treating
osteoporosis in previous publication [40]. Since osteopor-
osis and osteoarthritis were commonly seen in menopausal
and post-menopausal female, the CHM prescriptions for
these two diseases were similar.Table 4 The most common prescription patterns for combina
with osteoarthritis in Taiwan during 2002 (total prescription










Ge-gen, Xue-fu-chu-yu-tang“Xu-duan" was the second most commonly used
Chinese single herb for OA. It was shown to increase bone
mineral density and also had osteo-protective effect in ani-
mal model [49,50]. “Xu-dan” can also improve degener-
ation of cartilage and bone in the OA mice model [51].
The third common one to treat OA was “Nui-xi”. It could
improve bone mineral density and relieve the swelling
joint in the OA rat model [52].
Our results showed that the most common combin-
ation of two CHMs was “Du-huo-ji-sheng-tang plus
Shu-jiang-hou-xie-tang” in treating OA, followed by
“Jia-wei-xiao-yao-san plus Du-huo-ji-sheng-tang” and
“Jia-wei-xiao-yao-san plus Shu-jing-huo-zue-tang.” “Jia-tion Chinese herbs in a single prescription for subjects
numbers = 32,050)











Table 5 The most common prescription patterns for the triple drug combination of Chinese herbs for subjects with
osteoarthritis in Taiwan during 2002 (total prescription numbers = 32,050)
Chinese herbal formulae or single herbs Support (%) Number of prescriptions
Du-huo-ji-sheng-tang, Gu-sui-pu, Xu-duan 0.5% 154
Du-huo-ji-sheng-tang, Yan-hu-suo, Niu-xi 0.4% 133
Du-huo-ji-sheng-tang, Shu-jing-huo-xue-tang, Yan-hu-suo 0.4% 132
Du-zhong, Xu-duan, Gu-sui-pu. 0.4% 130
Du-zhong, Wei-ling-xian, Xu-duan 0.4% 124
Du-huo-ji-sheng-tang, Shu-jing-huo-xue-tang, Wei-ling-xian 0.4% 123
Du-huo-ji-sheng-tang, Wei-ling-xian, Xu-duan 0.4% 118
Du-huo-ji-sheng-tang, Wei-ling-xian, Niu-xi 0.4% 113
Du-zhong, Xu-duan, Ji-xue-teng 0.3% 107
Ji-sheng-shen-qi-wan, Du-zhong, Mu-gua 0.3% 106
Chen et al. BMC Complementary and Alternative Medicine 2014, 14:91 Page 6 of 8
http://www.biomedcentral.com/1472-6882/14/91wei-xiao-yao-san” (Dan-zhi-xiao-yao-san) was com-
monly used in menopausal female to ameliorate meno-
pausal symptoms [53], so the menopausal women with
OA were frequently prescribed with these two formulae.
The most commonly combination of three CHMs is
“Du-huo-ji-sheng-tang, Gu-sui-pu plus Xu-duan”, followed
by “Du-huo-ji-sheng-tang, Yan-hu-suo plus Nui-xi” and
“Du-huo-ji-sheng-tang, Shu-jing-huo-zue-tang plus Yan-
hu-suo.” “Gu-sui-pu” could inhibit the osteoclast activity in
the OA mouse model [54] and prevent osteoporosis [55].
And “Yan-hu-suo” had anti-inflammatory effect with de-
creasing vascular permeability and restraining the develop-
ment of adjuvant-induced edema in arthritic mice and rat
models [56]. It also could alleviate pain with analgesic effect
in a rat model [57].
TCM doctors in Taiwan frequently prescribe a com-
bination of Chinese herbal formulae and Chinese single
herb with the concepts of “pattern identification as the
basis for determining treatment” and “sovereign, minis-
ter, assistant, and courier” [33,35,37]. Mostly, there were
six items of CHM in a prescription for OA. Since female
OA patients usually combined with menopausal syn-
drome and osteoporosis, the TCM doctors might com-
bine use these CHM formulae more frequently in order
to treat these two diseases.
There were some limitations in this study: (1) The
diagnosis of OA among TCM doctors might mix with
rheumatoid arthritis and other arthropathy or connect-
ive tissue disease, since the joint pain or arthralgia were
similar. This might explain that the highest prevalence
of OA in our study was 40-49 years, while OA is known
to be a degenerative disease which commonly seen in
elderly. (2) We only analyzed the utilization of CHM for
treating OA, the utilization of acupuncture and Chinese
tuina in treating OA were not included. (3) Since the
therapeutic effectiveness of TCM for OA is not evalu-
ated in this study, further efficacy studies will be exe-
cuted in the future.Conclusions
This pharmaco-epidemiological study showed higher
utilization of Chinese herbal medicine use of OA patients
in the 40-49 age group and female patients, with
Du-zhong (Eucommia bark) and Du-huo-ji-sheng-tang be-
ing the most commonly prescribed single herb and herbal
formula, respectively.
The most common single herb and Chinese herbal for-
mula are “Du-zhong” and Chinese “Du-huo-ji-sheng-tang.”
The most common combination of two CHMs and triple
CHMs are “Shu-jiang-hou-xie-tang plus Du-huo-ji-sheng-
tang” and “Du-huo-ji-sheng-tang, Gu-sui-pu plus Xu-
duan.” However, the therapeutic effects and safety of these
CHM in treating OA still need to elucidate with well-
defined randomized, double-blind, placebo-controlled clin-
ical trials for further study.
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